The tradipitant saga stretches back to September 2024, when the FDA declined to approve Vanda’s drug in gastroparesis, a ...

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

Where thousands of former Health and Human Services employees will work next is unknown, but biopharma companies likely ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment landscape for head and neck and lung cancer, and implications for specific drug ...

Merck, Bristol Myers Squibb, Sanofi and Roche had little clarity on the potential impact of President Donald Trump’s ...

Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.

The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca ...

Despite a dip in sales and a recent schizophrenia stumble, the company drew an optimistic outlook for sales for the rest of ...

In this episode presented by DIA, BioSpace's head of insights Lori Ellis discusses the underrepresentation of women in ...

Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., ...

With a new raise provided by Flagship Pioneering, the new company is aiming to find “the silent window” before disease symptoms set in.